Close Menu

intellectual property

NKT licensed the IP from Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital. As a result, each of the Harvard Med-affiliated institutes has been awarded an undisclosed equity stake in the company.

The deal is a result of a nearly three-year research partnership between Aphios and LSUHSC-S, and is the latest product of a concerted effort at LSUHSC-S to ramp up collaboration between its faculty and industry.

The deal brings to six the number of academic institutions from which Fate has licensed IP related to using small molecules to induce pluripotency in stem cells for therapeutic effect, drug discovery, and matched cell-replacement therapies.

The patent, called “Fragment Complementation Assays for G Protein-Coupled Receptors and Their Signaling Pathways,” solidifies Odyssey’s position in complex-based assays, and adds depth to its IP coverage in these two areas, an Odyssey official told CBA News this week.

Pages

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.